Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051293191> ?p ?o ?g. }
- W2051293191 endingPage "3810" @default.
- W2051293191 startingPage "3803" @default.
- W2051293191 abstract "The studies concerning clinical implications of TET2 mutation in patients with primary acute myeloid leukemia (AML) are scarce. We analyzed TET2 mutation in 486 adult patients with primary AML. TET2 mutation occurred in 13.2% of our patients and was closely associated with older age, higher white blood cell and blast counts, lower platelet numbers, normal karyotype, intermediate-risk cytogenetics, isolated trisomy 8, NPM1 mutation, and ASXL1 mutation but mutually exclusive with IDH mutation. TET2 mutation is an unfavorable prognostic factor in patients with intermediate-risk cytogenetics, and its negative impact was further enhanced when the mutation was combined with FLT3-ITD, NPM1-wild, or unfavorable genotypes (other than NPM1(+)/FLT3-ITD(-) or CEBPA(+)). A scoring system integrating TET2 mutation with FLT3-ITD, NPM1, and CEBPA mutations could well separate AML patients with intermediate-risk cytogenetics into 4 groups with different prognoses (P < .0001). Sequential analysis revealed that TET2 mutation detected at diagnosis was frequently lost at relapse; rarely, the mutation was acquired at relapse in those without TET2 mutation at diagnosis. In conclusion, TET2 mutation is associated with poor prognosis in AML patients with intermediate-risk cytogenetics, especially when it is combined with other adverse molecular markers. TET2 mutation appeared to be unstable during disease evolution." @default.
- W2051293191 created "2016-06-24" @default.
- W2051293191 creator A5002091044 @default.
- W2051293191 creator A5004433315 @default.
- W2051293191 creator A5005003123 @default.
- W2051293191 creator A5005101214 @default.
- W2051293191 creator A5011302303 @default.
- W2051293191 creator A5014522958 @default.
- W2051293191 creator A5021275887 @default.
- W2051293191 creator A5023016883 @default.
- W2051293191 creator A5026844188 @default.
- W2051293191 creator A5032738660 @default.
- W2051293191 creator A5034651788 @default.
- W2051293191 creator A5040824187 @default.
- W2051293191 creator A5048892865 @default.
- W2051293191 creator A5055188409 @default.
- W2051293191 creator A5057493417 @default.
- W2051293191 creator A5059115571 @default.
- W2051293191 creator A5064923597 @default.
- W2051293191 creator A5069220782 @default.
- W2051293191 creator A5071037877 @default.
- W2051293191 creator A5073998614 @default.
- W2051293191 creator A5080199901 @default.
- W2051293191 creator A5084078138 @default.
- W2051293191 creator A5084658530 @default.
- W2051293191 creator A5090611097 @default.
- W2051293191 date "2011-10-06" @default.
- W2051293191 modified "2023-10-12" @default.
- W2051293191 title "TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics" @default.
- W2051293191 cites W1489375841 @default.
- W2051293191 cites W1492609361 @default.
- W2051293191 cites W1966812152 @default.
- W2051293191 cites W1969276101 @default.
- W2051293191 cites W1978544029 @default.
- W2051293191 cites W1978614428 @default.
- W2051293191 cites W1981463058 @default.
- W2051293191 cites W1990710680 @default.
- W2051293191 cites W1994467709 @default.
- W2051293191 cites W1998598673 @default.
- W2051293191 cites W2010714616 @default.
- W2051293191 cites W2012080286 @default.
- W2051293191 cites W2020160910 @default.
- W2051293191 cites W2026310796 @default.
- W2051293191 cites W2035543326 @default.
- W2051293191 cites W2040365591 @default.
- W2051293191 cites W2040399202 @default.
- W2051293191 cites W2043387647 @default.
- W2051293191 cites W2047196883 @default.
- W2051293191 cites W2057867563 @default.
- W2051293191 cites W2059150276 @default.
- W2051293191 cites W2061653945 @default.
- W2051293191 cites W2063280000 @default.
- W2051293191 cites W2067797084 @default.
- W2051293191 cites W2073872690 @default.
- W2051293191 cites W2075808651 @default.
- W2051293191 cites W2078972833 @default.
- W2051293191 cites W2079901663 @default.
- W2051293191 cites W2082312262 @default.
- W2051293191 cites W2082448876 @default.
- W2051293191 cites W2083109253 @default.
- W2051293191 cites W2097743943 @default.
- W2051293191 cites W2100372406 @default.
- W2051293191 cites W2107715878 @default.
- W2051293191 cites W2108664872 @default.
- W2051293191 cites W2109150359 @default.
- W2051293191 cites W2111737305 @default.
- W2051293191 cites W2112129429 @default.
- W2051293191 cites W2126274764 @default.
- W2051293191 cites W2131860315 @default.
- W2051293191 cites W2138623699 @default.
- W2051293191 cites W2152573813 @default.
- W2051293191 cites W2162619595 @default.
- W2051293191 cites W2167348350 @default.
- W2051293191 cites W2169172058 @default.
- W2051293191 cites W2170515966 @default.
- W2051293191 cites W2170666362 @default.
- W2051293191 doi "https://doi.org/10.1182/blood-2011-02-339747" @default.
- W2051293191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21828143" @default.
- W2051293191 hasPublicationYear "2011" @default.
- W2051293191 type Work @default.
- W2051293191 sameAs 2051293191 @default.
- W2051293191 citedByCount "266" @default.
- W2051293191 countsByYear W20512931912012 @default.
- W2051293191 countsByYear W20512931912013 @default.
- W2051293191 countsByYear W20512931912014 @default.
- W2051293191 countsByYear W20512931912015 @default.
- W2051293191 countsByYear W20512931912016 @default.
- W2051293191 countsByYear W20512931912017 @default.
- W2051293191 countsByYear W20512931912018 @default.
- W2051293191 countsByYear W20512931912019 @default.
- W2051293191 countsByYear W20512931912020 @default.
- W2051293191 countsByYear W20512931912021 @default.
- W2051293191 countsByYear W20512931912022 @default.
- W2051293191 countsByYear W20512931912023 @default.
- W2051293191 crossrefType "journal-article" @default.
- W2051293191 hasAuthorship W2051293191A5002091044 @default.
- W2051293191 hasAuthorship W2051293191A5004433315 @default.
- W2051293191 hasAuthorship W2051293191A5005003123 @default.